Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19054696 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | February 2025 | September 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18949272 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | November 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18829566 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | September 2024 | November 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18821027 | AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALT | August 2024 | May 2025 | Allow | 8 | 2 | 0 | No | No |
| 18800436 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | August 2024 | January 2026 | Allow | 17 | 3 | 1 | Yes | No |
| 18800392 | PROCESS FOR PREPARING A GIP/GLP1 DUAL AGONIST | August 2024 | January 2026 | Abandon | 17 | 3 | 0 | No | No |
| 18640964 | AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALT | April 2024 | May 2024 | Allow | 1 | 0 | 0 | Yes | No |
| 18618780 | GLUCOSE-RESPONSIVE INSULIN ANALOGS AND METHODS OF USE THEREOF | March 2024 | October 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18431596 | FIBROIN-DERIVED PROTEIN COMPOSITION | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18392459 | STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAME | December 2023 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18392545 | DOSING REGIMENS | December 2023 | November 2025 | Allow | 23 | 4 | 1 | Yes | No |
| 18518879 | COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTS | November 2023 | January 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18518880 | COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTS | November 2023 | January 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18287276 | PROCOAGULANT PEPTIDES AND USE THEREOF | October 2023 | March 2026 | Allow | 29 | 0 | 0 | Yes | No |
| 18285543 | PEPTIDE HAVING BLOOD COAGULATION ACTIVITY, AND USE THEREOF | October 2023 | March 2026 | Allow | 29 | 0 | 0 | No | No |
| 18476587 | GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS | September 2023 | December 2024 | Allow | 14 | 1 | 0 | No | No |
| 18468151 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | September 2023 | September 2025 | Allow | 24 | 2 | 1 | No | No |
| 18460024 | SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATION | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18452479 | PEPTIDIC DIAGNOSTIC COMPOSITIONS | August 2023 | March 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18363810 | THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUES | August 2023 | August 2024 | Allow | 13 | 0 | 0 | No | No |
| 18355240 | SYNTHETIC LUNG SURFACTANT WITH ENHANCED STABILITY AND EFFECTIVENESS | July 2023 | February 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18347246 | LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USE | July 2023 | June 2024 | Allow | 11 | 1 | 0 | No | No |
| 18203371 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | May 2023 | October 2024 | Allow | 17 | 0 | 0 | No | No |
| 18320638 | USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK | May 2023 | March 2024 | Abandon | 10 | 1 | 0 | No | No |
| 18142470 | METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION | May 2023 | July 2024 | Allow | 14 | 2 | 0 | No | No |
| 18296801 | USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK | April 2023 | April 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18247584 | AMYLOID-beta AGGREGATION INHIBITOR, PHARMACEUTICAL COMPOSITION FORAMYLOID-beta AGGREGATION DISEASE, AND USE APPLICATION OF SAME | March 2023 | March 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18187639 | De Novo Design of Potent and Selective Interleukin Mimetics | March 2023 | October 2024 | Allow | 19 | 1 | 1 | No | No |
| 18121384 | COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTS | March 2023 | June 2025 | Abandon | 27 | 5 | 0 | No | No |
| 18176903 | SILK-BASED PRODUCT FORMULATIONS AND METHODS OF USE | March 2023 | July 2025 | Allow | 28 | 3 | 0 | No | No |
| 18115744 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | February 2023 | March 2025 | Allow | 24 | 3 | 0 | Yes | No |
| 18168438 | STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME | February 2023 | February 2024 | Allow | 12 | 0 | 0 | No | No |
| 18164515 | COMPOSITION FOR IMPROVING HAIR HEALTH | February 2023 | March 2025 | Allow | 25 | 4 | 0 | Yes | No |
| 18152624 | COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF | January 2023 | April 2024 | Abandon | 16 | 1 | 1 | No | No |
| 18151957 | ANG (1-7) DERVIATIVE OLIGOPEPTIDES FOR THE TREATMENT OF PAIN | January 2023 | August 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18150246 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | January 2023 | April 2025 | Allow | 27 | 3 | 1 | No | No |
| 18013389 | V1A Receptor Partial Agonist and Method of Use | December 2022 | April 2025 | Allow | 28 | 1 | 1 | Yes | No |
| 18068838 | METHODS AND SYSTEMS FOR SOLID PHASE PEPTIDE SYNTHESIS | December 2022 | March 2024 | Allow | 15 | 1 | 0 | No | No |
| 18084155 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERS | December 2022 | September 2024 | Allow | 21 | 2 | 1 | No | No |
| 18083811 | MIC-1 COMPOUNDS AND USE THEREOF | December 2022 | February 2024 | Allow | 14 | 1 | 1 | No | No |
| 18008006 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | December 2022 | January 2026 | Abandon | 37 | 0 | 1 | No | No |
| 17987137 | COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF LAR FAMILY PHOSPHATASES | November 2022 | August 2024 | Allow | 21 | 1 | 1 | No | No |
| 18053701 | PTH Compounds with Low Peak-To-Trough Ratios | November 2022 | September 2023 | Allow | 11 | 1 | 0 | Yes | No |
| 18050964 | TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOR | October 2022 | September 2024 | Allow | 22 | 1 | 0 | Yes | No |
| 18048262 | METHOD AND COMBINATION FOR THE SUPPRESSION OF COVID-19 VIRUS | October 2022 | March 2025 | Allow | 29 | 4 | 1 | Yes | No |
| 17964903 | DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF FOR FAT LOSS | October 2022 | June 2024 | Abandon | 20 | 2 | 0 | No | No |
| 17938861 | STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAME | October 2022 | September 2023 | Allow | 12 | 1 | 0 | No | No |
| 17995527 | ALISPORIVIR FOR USE IN HUMAN VIRAL INFECTIONS | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17906978 | CYCLOPHILIN INHIBITORS AND USES THEREOF | September 2022 | September 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17913372 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMPHIPHILIC PEPTIDES AND METHODS OF USE THEREOF | September 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17912907 | CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPY | September 2022 | April 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17932230 | COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASES | September 2022 | June 2024 | Abandon | 21 | 2 | 0 | No | No |
| 17909054 | COMPOSITIONS CONTAINING RAPID-ACTING INSULIN ANALOGUES | September 2022 | January 2026 | Allow | 40 | 1 | 1 | No | No |
| 17898994 | HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSIS | August 2022 | October 2023 | Allow | 14 | 1 | 0 | No | No |
| 17898384 | Anti-CD70 Antibody Drug Conjugates | August 2022 | October 2023 | Allow | 14 | 0 | 0 | No | No |
| 17893944 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | August 2022 | September 2025 | Allow | 37 | 4 | 0 | No | No |
| 17880271 | METHODS FOR REDUCING CD36 EXPRESSION | August 2022 | March 2025 | Abandon | 31 | 2 | 0 | No | Yes |
| 17814818 | OPHTHALMIC COMPOSITIONS COMPRISING CICLOSPORIN | July 2022 | April 2024 | Abandon | 20 | 2 | 0 | No | No |
| 17864829 | CYCLOPEPTIDE AND METHOD FOR PREPARING THE SAME | July 2022 | January 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 17811625 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | July 2022 | January 2026 | Allow | 43 | 1 | 0 | No | No |
| 17861353 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | July 2022 | December 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17851615 | SYNTHETIC LUNG SURFACTANT WITH ENHANCED STABILITY AND EFFECTIVENESS | June 2022 | August 2023 | Abandon | 14 | 1 | 0 | No | No |
| 17788688 | COMPOUND FOR THE TREATMENT OF THE HEMOLYTIC-UREMIC SYNDROME | June 2022 | July 2025 | Allow | 37 | 1 | 0 | No | No |
| 17837736 | PEPTIDE ANALOGS | June 2022 | June 2024 | Allow | 24 | 1 | 0 | No | No |
| 17783224 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | June 2022 | March 2025 | Allow | 33 | 1 | 0 | No | No |
| 17831017 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | June 2022 | October 2024 | Allow | 28 | 2 | 1 | No | No |
| 17781494 | COMBINATION THERAPY USING GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17731965 | LUNG-SPECIFIC TARGETING-PEPTIDE (LTP), COMPOSITIONS, AND USES THEREOF | April 2022 | March 2026 | Allow | 46 | 1 | 1 | No | No |
| 17726731 | MUSCLE QUALITY IMPROVEMENT AGENT | April 2022 | March 2026 | Allow | 47 | 2 | 1 | No | No |
| 17770826 | FILAMENTOUS NANOSTRUCTURES AND THEIR USE FOR TREATMENT OF PULMONARY DISEASE | April 2022 | January 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17725340 | IMMUNOMODULATORS | April 2022 | October 2023 | Allow | 18 | 1 | 0 | No | No |
| 17768356 | TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | April 2022 | April 2025 | Allow | 37 | 1 | 0 | No | No |
| 17767508 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | April 2022 | February 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17430864 | NOVEL INTERMEDIATE USED FOR PHYSIOLOGICALLY ACTIVE POLYPEPTIDES AND METHOD FOR PREPARING THE SAME. | March 2022 | December 2025 | Allow | 52 | 1 | 0 | No | No |
| 17762873 | NOVEL POLYMORPH FORM OF (R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOF | March 2022 | September 2023 | Allow | 18 | 2 | 0 | Yes | No |
| 17763185 | METHOD FOR PRODUCING PEPTIDE COMPOUND | March 2022 | September 2025 | Allow | 42 | 1 | 1 | No | No |
| 17761753 | Method of Treatment | March 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17698553 | De Novo Design of Potent and Selective Interleukin Mimetics | March 2022 | September 2024 | Allow | 30 | 0 | 0 | No | No |
| 17760596 | SUBCUTANEOUSLY INJECTABLE INSULIN AND GLUCAGON FORMULATIONS AND METHODS OF ADMINISTRATION | March 2022 | May 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17642131 | POLYPEPTIDES MIMICKING EPITOPE OF BROADLY NEUTRALIZING ANTIBODY VRC01 AS ANTIGENS FOR A VACCINE PREVENTING HIV-1 INFECTION | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17642096 | NEUROLOGICAL DISEASE TREATMENT WITH COMPLEMENT INHIBITORS | March 2022 | February 2026 | Abandon | 48 | 2 | 1 | No | No |
| 17641058 | MITIGATION OF PERI-IMPLANTITIS BY DESIGN AND STABILITY OF BIFUNCTIONAL PEPTIDES WITH ANTIMICROBIAL PROPERTIES | March 2022 | September 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17640679 | OPHTHALMIC COMPOSITION FOR THE TREATMENT OF UVEITIS | March 2022 | May 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17684267 | COMPOSITIONS AND USES OF ANTIMICROBIAL MATERIALS WITH TISSUE-COMPATIBLE PROPERTIES | March 2022 | February 2024 | Allow | 23 | 2 | 0 | No | No |
| 17638930 | PEPTIDE INHIBITORS OF FOCAL ADHESION KINASE ACTIVITY AND USES THEREOF | February 2022 | January 2026 | Allow | 47 | 2 | 1 | Yes | No |
| 17634499 | THERAPEUTIC PEPTIDES | February 2022 | April 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17634490 | THERAPEUTIC PEPTIDES | February 2022 | April 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17631821 | MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | January 2022 | December 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17583956 | SELECTIVE MENA BINDING PEPTIDES | January 2022 | October 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17629460 | RECEPTOR-TARGETING PEPTIDE-DRUG CONJUGATES | January 2022 | September 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17629501 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | January 2022 | May 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17628552 | ANTIBACTERIAL PEPTIDE DERIVED FROM ERYTHROCULTER ILISHAEFORMIS AND USE THEREOF | January 2022 | December 2024 | Allow | 35 | 1 | 0 | No | No |
| 17648137 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | January 2022 | April 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17624830 | A TEIXOBACTIN ANALOGUE AND USE THEREOF | January 2022 | May 2025 | Allow | 40 | 2 | 0 | No | No |
| 17560420 | STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDS | December 2021 | July 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17619918 | ROMO1-DERIVED ANTIMICROBIAL PEPTIDES INCLUDING LYSINE SUBSTITUTION AND VARIANTS THEREOF | December 2021 | July 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17619913 | ROMO1-DERIVED ANTIMICROBIAL PEPTIDES AND VARIANTS THEREOF | December 2021 | April 2024 | Allow | 28 | 2 | 0 | No | No |
| 17619502 | STABLE FORMULATION OF CETRORELIX | December 2021 | March 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17643527 | CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATING MATERIAL, AND MEDIUM | December 2021 | January 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17540448 | Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins | December 2021 | September 2025 | Abandon | 45 | 4 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BRADLEY, CHRISTINA.
With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 9.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BRADLEY, CHRISTINA works in Art Unit 1654 and has examined 931 patent applications in our dataset. With an allowance rate of 61.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner BRADLEY, CHRISTINA's allowance rate of 61.8% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BRADLEY, CHRISTINA receive 1.54 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by BRADLEY, CHRISTINA is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +31.6% benefit to allowance rate for applications examined by BRADLEY, CHRISTINA. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.2% of applications are subsequently allowed. This success rate is in the 43% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 79.2% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 89.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 59.6% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 17.7% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.